X

Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot

— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.

— Revenue rose 16% to $69.6 million vs. $93.15 million expected.

— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.

— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.

— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.

— AKBA stock dipped more than 5% in the pre-market trading session.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Related Post